DR. WEI CHUN GOH, M.D. PH.D.
Medical Practice at Washington St, Boston, MA
License number
Massachusetts 216407
Category
Medical Practice
Type
Specialist
Address
Address
2
750 Washington St, Boston, MA 02111
14 Porter St, Somerville, MA 02143
14 Porter St, Somerville, MA 02143
Phone
(617) 636-7087
(617) 636-3216 (Fax)
(617) 636-3216 (Fax)
Personal information
See more information about WEI CHUN GOH at radaris.comName
Address
Phone
14 Porter St, Somerville, MA 02143
Professional information
Dr. Wei Chun Goh, Boston MA - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
750 Washington St, Boston 02111
(617) 636-7087 (Phone), (617) 636-3216 (Fax)
(617) 636-7087 (Phone), (617) 636-3216 (Fax)
Certifications:
Critical Care Medicine, 2008, Internal Medicine, 2004, Pulmonary Disease, 2006
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Stanford University
Stanford University
Wei Chun Goh, Boston MA
Specialties:
Internal Medicine, Infectious Disease
Work:
Tufts Medical Center
750 Washington St, Boston, MA 02111
750 Washington St, Boston, MA 02111
Education:
Stanford University (1990)
Wei Chun Chun Goh, Martinez CA
Specialties:
Infectious Disease Specialist
Address:
150 Muir Rd, Martinez, CA 94553
750 Washington St, Boston, MA 02111
750 Washington St, Boston, MA 02111
Art Nucleotide Segments, Vectors, Cell Lines Methods Of Preparation And Use
US Patent:
4935372, Jun 19, 1990
Filed:
May 20, 1986
Appl. No.:
6/865151
Inventors:
Wei C. Goh - Somerville MA
Assignee:
Dana Farber Cancer Institute - Boston MA
International Classification:
C12N 1500, C12N 500, C07H 2104
US Classification:
4353171
Abstract:
A gene and gene product that regulates the expression of the capsidal envelope genes of HTLV-III/LAV and that can be used to regulate the expression of heterologous (non-viral) genes as well is disclosed. This art gene consists of two exons and can be used in creating nucleotide segments, vectors and cell lines. A new method for screening for compounds that inhibit the replication of HTLV-III is also described and comprises:
(1) transfecting a T-cell line with the HTLV-III art and env genes;
(2) thereafter, adding a preselected compound to the transformed cell line in increasing concentrations; and
(3) determining whether the compound effects the art function without being toxic to the cell.
An additional parameter to use in diagnosis of AIDS disease is also described. The use of the art gene and gene product in AIDS therapy is also disclosed.
Stable Tatiii Cell Lines, Tatiii Gene Products, And Assay Methods
US Patent:
4981790, Jan 1, 1991
Filed:
Dec 6, 1985
Appl. No.:
6/806263
Inventors:
William A. Haseltine - Cambridge MA
Craig A. Rosen - Brookline MA
Joseph G. Sodroski - Cambridge MA
Wei C. Goh - Somerville MA
Craig A. Rosen - Brookline MA
Joseph G. Sodroski - Cambridge MA
Wei C. Goh - Somerville MA
Assignee:
Dana Farber Cancer Institute - Boston MA
International Classification:
C12P 2100, C12N 1500, C12N 500
US Classification:
435 691
Abstract:
This invention describes stable tat. sub. III cell lines. It is disclosed that by transfecting a preselected tat. sub. III cell line with a vector containing a sufficient amount of the HTLV-III LTR responsive to tat. sub. III gene products for trans-activation and an enhancer upstream of the tat. sub. III responsive segment, it is possible to express high levels of the tat. sub. III gene products. By including a preselected heterologous gene on this vector, it is also possible to express high levels of a desired gene product. A substantially pure protein comprising 86 amino acids and having an apparent molecular weight of about 14,000 dalton and exhibiting trans-activating activity is also disclosed. This protein and polypeptides having trans-activating ability, which is also disclosed, can be used to produce high levels of a desired gene product. A method of detecting the presence of HTLV-III/LAV virus in an individual is also disclosed and comprises the step of:
(a) incubating whole blood or lymphocytes from the invididual to be tested with tat. sub.
Assay Methods For Tat Cell Lines
US Patent:
5800986, Sep 1, 1998
Filed:
Jun 1, 1995
Appl. No.:
8/456346
Inventors:
William Alan Haseltine - Cambridge MA
Craig A. Rosen - Brookline MA
Joseph Gerald Sodroski - Cambridge MA
Wei Chun Goh - Somerville MA
Craig A. Rosen - Brookline MA
Joseph Gerald Sodroski - Cambridge MA
Wei Chun Goh - Somerville MA
Assignee:
Dana Farber Cancer Institute - Boston MA
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
Assays screened for compounds that inhibit tat transactivation of the HIV (HTLV-III) LTR are taught. The assay involves tranfecting a cell line containing the tat gene by a vector containing a gene under the control of an HIV-1 LTR, adding the compound to be screened and determining the effect of the compound by looking at the effect of tat as measured by the expression of the gene under the control of the HIV LTR.
Art (Rev) Protein Of Human T-Cell Leukemia Virus
US Patent:
5321124, Jun 14, 1994
Filed:
Dec 18, 1992
Appl. No.:
7/995948
Inventors:
William A. Haseltine - Cambridge MA
Craig A. Rosen - Brookline MA
Joseph G. Sodroski - Cambridge MA
Wei C. Goh - Somerville MA
Craig A. Rosen - Brookline MA
Joseph G. Sodroski - Cambridge MA
Wei C. Goh - Somerville MA
Assignee:
Dana Farber Cancer Institute - Boston MA
International Classification:
C07K 1300
US Classification:
530350
Abstract:
A gene and gene product that regulates the expression of the capsidal envelope genes of HTLV-III/LAV and that can be used to regulate the expression of heterologous (non-viral) genes as well is disclosed. This art gene consists of two exons and can be used in creating nucleotide segments, vectors and cell lines. A new method for screening for compounds that inhibit the replication of HTLV-III is also described and comprises:
(1) transfecting a T-cell line with the HTLV-III art and env genes;
(2) thereafter, adding a preselected compound to the transformed cell line in increasing concentrations; and
(3) determining whether the compound effects the art function without being toxic to the cell.
An additional parameter to use in diagnosis of AIDS disease is also described. The use of the art gene and gene product in AIDS therapy is also disclosed.